exoASO-C/EBPβ / Codiak - LARVOL DELTA

exoASO-C/EBPβ™: An engineered exosome therapeutic that selectively targets MDSCs and induces potent single-agent anti-tumor activity in checkpoint refractory tumor models (SITC 2022) - "Finally, a myeloid cell specific C/EBPβ/PGE2/IL10 gene signature was generated to identify cancer indications where exoASO-C/EBPβ therapy may have the most therapeutic significance. Conclusions exoASO-C/EBPβ is a novel therapeutic that selectively targets and attenuates a critical transcription factor in immunosuppressive myeloid derived suppressor cells, resulting in their immune-modulation and potent anti-tumor activity across multiple MDSC rich tumor models."

IO biomarker • Preclinical • Bladder Cancer • Breast Cancer • Genito-urinary Cancer • Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer • CD14 • CD33 • CD8 • IL10 • ITGAM

Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages (GlobeNewswire) - "Codiak BioSciences...announced that two posters featuring preclinical data from its engEx® Platform programs will be presented during the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022)....'At SITC, we will present new preclinical data on two of our systemically administered exosome therapeutic candidates which target macrophages and have previously demonstrated potent monotherapy activity in preclinical models....Both exoASO™-STAT6 and exoASO™-C/EBPβ specifically inhibit transcription factors in distinct macrophage subpopulations by leveraging engineered exosomes to selectively target pathways known to play a critical role in tumor immunology'."

Preclinical • Oncology

Exosome-mediated delivery of antisense oligonucleotides targeting C/EBPβ reprograms tumor-associated macrophages and induces potent single agent anti-tumor activity (AACR 2022) - "exoASO-C/EBPβ is a novel therapeutic candidate that selectively targets and attenuates a critical transcription factor in immunosuppressive myeloid cells, resulting in reprogramming of TAMs and potent anti-tumor activity across multiple TAM-rich mouse models as a monotherapy."

IO biomarker • Bladder Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Melanoma • Oncology • Solid Tumor • Urothelial Cancer • CSF1R • IL10 • ITGAM • MRC1 • NOS2 • TNFA

Codiak’s exoASO-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloid Cells (Yahoo Finance) - "Codiak BioSciences, Inc...today announced new preclinical data on the Company’s engineered exosome precision medicine candidate, exoASO-C/EBPβ. The data, which will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, demonstrate that exoASO-C/EBPβ induces potent single-agent anti-tumor activity by repolarizing myeloid cells in the tumor and blood to induce an immune response."

Preclinical • Oncology